NASDAQ:ACAD

ACADIA Pharmaceuticals (ACAD) Stock Forecast, Price & News

$21.47

+0.63 (+3.02%)

(As of 10/2/2023 ET)

Compare

Today's Range: $20.31
▼
$21.52
50-Day Range: $20.84
▼
$30.32
52-Week Range: $13.73
▼
$33.99

Volume: 2.40 million shs
Average Volume: 1.59 million shs
Market Capitalization: $3.52 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $31.81

ACADIA Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Hold
2.38 Rating Score
Upside/Downside: 48.2% Upside
$31.81 Price Target
Short Interest: Bearish
6.54% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.18
Based on 7 Articles This Week
Insider Trading: Selling Shares
$3.76 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.41) to $0.60 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Medical Sector

273rd out of 969 stocks

Pharmaceutical Preparations Industry

108th out of 452 stocks

4.2

Analyst's Opinion

Consensus Rating
ACADIA Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 6 buy ratings, 6 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $31.81, ACADIA Pharmaceuticals has a forecasted upside of 48.2% from its current price of $21.47.
Amount of Analyst Coverage
ACADIA Pharmaceuticals has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
6.54% of the outstanding shares of ACADIA Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
ACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 6.6.
Change versus previous month
Short interest in ACADIA Pharmaceuticals has recently increased by 5.11%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
ACADIA Pharmaceuticals does not currently pay a dividend.
Dividend Growth
ACADIA Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ACAD.

2.3

News and Social Media Coverage

News Sentiment
ACADIA Pharmaceuticals has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for ACADIA Pharmaceuticals this week, compared to 4 articles on an average week.
Search Interest
Only 4 people have searched for ACAD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
5 people have added ACADIA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ACADIA Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,758,210.00 in company stock.
Percentage Held by Insiders
27.50% of the stock of ACADIA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
96.29% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for ACADIA Pharmaceuticals are expected to grow in the coming year, from ($0.41) to $0.60 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ACADIA Pharmaceuticals is -31.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ACADIA Pharmaceuticals is -31.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ACADIA Pharmaceuticals has a P/B Ratio of 8.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.

ACAD Price History

30 days | 90 days | 365 days | Advanced Chart

ACAD Stock News Headlines

October 1, 2023 | americanbankingnews.com

ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Down 2.5%

September 30, 2023 | americanbankingnews.com

ACADIA Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:ACAD)

October 2, 2023 | Stansberry Research (Ad)

Is NVIDIA Leading a "Magnificent Seven Bubble"?

The world’s massive tech leaders may be in a bubble, led by NVIDIA’s enormous rise this year. What happens next could affect all stocks.

September 28, 2023 | seekingalpha.com

Acadia Pharma falls after patent hearing in dispute with MSN

September 28, 2023 | americanbankingnews.com

ACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Pass Above 200-Day Moving Average of $24.15

September 23, 2023 | seekingalpha.com

Daybue Drives Acadia Pharmaceuticals To Positive Earnings (Rating Upgrade)

September 19, 2023 | finance.yahoo.com

Acadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications

September 13, 2023 | ca.finance.yahoo.com

ACAD - ACADIA Pharmaceuticals Inc.

October 2, 2023 | Stansberry Research (Ad)

Is NVIDIA Leading a "Magnificent Seven Bubble"?

The world’s massive tech leaders may be in a bubble, led by NVIDIA’s enormous rise this year. What happens next could affect all stocks.

September 1, 2023 | finance.yahoo.com

Acadia (ACAD) Down 0.7% Since Last Earnings Report: Can It Rebound?

August 25, 2023 | finance.yahoo.com

Dry Eye Syndrome Global Market Report 2023

August 25, 2023 | theglobeandmail.com

Betting Big On Biotech: Six Undervalued Biotech Stocks To Keep On Your Radar

August 25, 2023 | thestreet.com

Acadia Pharmaceuticals Stock Has Fallen Too Far Recently

August 23, 2023 | markets.businessinsider.com

H.C. Wainwright upgrades Fulcrum Therapeutics (FULC) to a Buy

August 22, 2023 | fool.com

Can This Red-Hot Biotech Stock Keep Beating the Broader Markets?

August 16, 2023 | markets.businessinsider.com

Zynerba Pharmaceuticals (ZYNE) was downgraded to a Hold Rating at Canaccord Genuity

August 11, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Theseus Pharmaceuticals (THRX)

August 10, 2023 | finance.yahoo.com

Here's Why Acadia (ACAD) Looks Ripe for Bottom Fishing

August 10, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)

August 9, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: ClearPoint Neuro (CLPT), Terns Pharmaceuticals (TERN)

August 8, 2023 | markets.businessinsider.com

Syros Pharmaceuticals (SYRS) Gets a Buy from JMP Securities

August 8, 2023 | msn.com

JP Morgan Maintains Acadia Pharmaceuticals (ACAD) Neutral Recommendation

August 8, 2023 | markets.businessinsider.com

JP Morgan Maintains Neutral Rating for ACADIA Pharmaceuticals: Here's What You Need To Know

August 3, 2023 | msn.com

Oppenheimer Reiterates Acadia Pharmaceuticals (ACAD) Perform Recommendation

August 3, 2023 | msn.com

Canaccord Genuity Maintains Acadia Pharmaceuticals (ACAD) Buy Recommendation

August 3, 2023 | finance.yahoo.com

Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat Estimates

August 2, 2023 | seekingalpha.com

ACADIA Pharmaceuticals Inc. 2023 Q2 - Results - Earnings Call Presentation

See More Headlines

Receive ACAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACAD Company Calendar

Last Earnings: 8/02/2023
Today: 10/02/2023
Next Earnings (Estimated): 11/01/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ACAD
CUSIP: N/A
CIK: 1070494
Web: www.acadia-pharm.com
Phone: (858) 558-2871
Fax: 858-558-2872
Employees: 540
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $31.81
High Stock Price Forecast: $95.00
Low Stock Price Forecast: $12.00
Forecasted Upside/Downside: +49.8%
Consensus Rating: Hold
Rating Score (0-4): 2.38
Research Coverage: 13 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.69)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-215,980,000.00
Net Margins: -20.11%
Pretax Margin: -19.22%
Return on Equity: -27.77%
Return on Assets: -17.81%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.62
Quick Ratio: 2.57

Sales & Book Value

Annual Sales: $517.23 million
Price / Sales: 6.72
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.47 per share
Price / Book: 8.60

Miscellaneous

Outstanding Shares: 163,730,000
Free Float: 118,704,000
Market Cap: $3.48 billion
Optionable: Optionable
Beta: 0.65

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Stephen R. Davis J.D. (Age 62)
Pres, CEO & Director
Comp: $1.46M

Mr. Mark C. Schneyer (Age 49)
Exec. VP & CFO
Comp: $701.03k

Mr. Brendan P. Teehan (Age 54)
Exec. VP, COO & Head of Commercial
Comp: $724.31k

Mr. Austin D. Kim (Age 59)
Exec. VP, Gen. Counsel & Sec.
Comp: $722.15k

Mr. James K. Kihara (Age 42)
VP, Chief Accounting Officer & Corp. Controller

Mr. Bob Mischler
Sr. VP of Strategy & Technology Operations

Mr. Mark C. Johnson
VP of Investor Relations

Ms. Julie Fisher
Sr. VP of Marketing & Commercial Strategy

Ms. Holly Valdiviez
Sr. VP & Head of Sales

Mr. Rob Ackles
Sr. VP & Chief People Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ACAD Stock - Frequently Asked Questions

Should I buy or sell ACADIA Pharmaceuticals stock right now?: 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ACAD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACAD, but not buy additional shares or sell existing shares.
View ACAD analyst ratings or view top-rated stocks.
What is ACADIA Pharmaceuticals' stock price forecast for 2023?: 13 Wall Street analysts have issued 1 year target prices for ACADIA Pharmaceuticals' stock. Their ACAD share price forecasts range from $12.00 to $95.00. On average, they expect the company's share price to reach $31.81 in the next year. This suggests a possible upside of 49.8% from the stock's current price.
View analysts price targets for ACAD or view top-rated stocks among Wall Street analysts.
How have ACAD shares performed in 2023?: ACADIA Pharmaceuticals' stock was trading at $15.92 on January 1st, 2023. Since then, ACAD stock has increased by 33.4% and is now trading at $21.24.
View the best growth stocks for 2023 here.
Are investors shorting ACADIA Pharmaceuticals?: ACADIA Pharmaceuticals saw a increase in short interest in September. As of September 15th, there was short interest totaling 10,700,000 shares, an increase of 5.1% from the August 31st total of 10,180,000 shares. Based on an average daily trading volume, of 1,620,000 shares, the days-to-cover ratio is presently 6.6 days.
View ACADIA Pharmaceuticals' Short Interest.
When is ACADIA Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our ACAD earnings forecast.
How were ACADIA Pharmaceuticals' earnings last quarter?: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) released its earnings results on Wednesday, August, 2nd. The biopharmaceutical company reported $0.01 EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.13. The biopharmaceutical company earned $165.20 million during the quarter, compared to analyst estimates of $163.86 million. ACADIA Pharmaceuticals had a negative trailing twelve-month return on equity of 27.77% and a negative net margin of 20.11%. The business's revenue for the quarter was up 22.7% compared to the same quarter last year. During the same period last year, the company earned ($0.21) earnings per share.
What ETFs hold ACADIA Pharmaceuticals' stock?: ETFs with the largest weight of ACADIA Pharmaceuticals (NASDAQ:ACAD) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), ALPS Medical Breakthroughs ETF (SBIO), Invesco Biotechnology & Genome ETF (PBE), First Trust NYSE Arca Biotechnology Index Fund (FBT), Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).

What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO?: 8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among the company's employees.
What other stocks do shareholders of ACADIA Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).
What is ACADIA Pharmaceuticals' stock symbol?: ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."
How do I buy shares of ACADIA Pharmaceuticals?: Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is ACADIA Pharmaceuticals' stock price today?: One share of ACAD stock can currently be purchased for approximately $21.24.
How much money does ACADIA Pharmaceuticals make?: ACADIA Pharmaceuticals (NASDAQ:ACAD) has a market capitalization of $3.48 billion and generates $517.23 million in revenue each year. The biopharmaceutical company earns $-215,980,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis.
How many employees does ACADIA Pharmaceuticals have?: The company employs 540 workers across the globe.
How can I contact ACADIA Pharmaceuticals?: ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.acadia-pharm.com. The biopharmaceutical company can be reached via phone at (858) 558-2871, via email at ir@acadia-pharm.com, or via fax at 858-558-2872.

This page (NASDAQ:ACAD) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial